SBS Stock News & Sentiment

A new study started yesterday as part of five clinical trials focusing on crofelemer for rare diseases like SBS-IF and MVID in various regions, including the US and EU. The first results from one of the trials are expected by the first half of 2025. Crofelemer, a plant-based drug from Jaguar Health, has received special designations from the FDA and EMA for these conditions.

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

The research is part of five clinical trials, including three proof-of-concept studies and two Phase 2 studies, focusing on crofelemer for rare diseases like SBS-IF and microvillus inclusion disease (MVID) in regions such as the US, EU, and MENA. Results from the proof-of-concept studies are expected to be available by the second quarter of 2025. Crofelemer, a new plant-based prescription drug from Jaguar, has received Orphan Drug Designation from both the FDA and the European Medicines Agency for SBS-IF and MVID.

It is advisable to keep Sabesp shares after the 3Q24 results because of positive trends, although the valuation does not provide a safety margin given the unstable Brazilian economy. The company's net revenues increased by 9.6% year-on-year to $987 million, thanks to tariff changes and the effects of privatization on its financial reporting. Additionally, operating costs decreased by 3.1% year-on-year, resulting in a solid EBITDA margin of 59.9%, while net income rose by 43.7% year-on-year to $201 million.

Companhia de Saneamento Básico do Estado de São Paulo - SABESP (NYSE:SBS) will hold its Q3 2024 Earnings Conference Call on November 12, 2024, at 9:00 AM ET. The company representatives include Luiz Tiberio, the IR Superintendent, Carlos Piani, the CEO, and Daniel Szlak, the Financial Director. Luiz Tiberio will start the call by greeting everyone.

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a healthcare company specializing in gastrointestinal issues, will share new results at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. These findings come from subgroup analyses of the main goal of the important Phase III clinical trial, STARS, which looked at how apraglutide affects adults with short bowel syndrome and intestinal failure based on their initial demographics and specific disease traits.

Sabesp (SBS) might be a good option for short-term investors wanting to take advantage of the recent price movements in strong stocks. It is among the stocks that have successfully met our criteria for short-term trading strategies.

Sabesp (SBS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Companhia de saneamento Basico Do Estado De Sao Paulo Sabesp (SBS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.